Gossamer Bio files first NDA for seralutinib in PAH; Q3 net loss $48.1M, cash $51.2M

Gossamer Bio, Inc.

2026-Q3 EPS reported -$25.61 revenue$64,624,000

NDA for seralutinib in PAH submitted to FDA in September 2026, backed by Phase 3 PROSERA plus Phase 2 TORREY; FDA acceptance would unlock ~$125M.
Q3 2026 revenue from collaborators $38.4M vs $13.3M a year earlier, driven by $25.1M recognized on the July 2026 Chiesi collaboration termination.
Net loss $48.1M ($7.36/share) vs $48.2M ($16.92/share) in Q3 2025; R&D fell to $18.8M from $45.5M on lower seralutinib trial costs; G&A $9.6M.
Cash, equivalents and marketable securities $51.2M at Sept 30, 2026, down from $57.0M at June 30; structured placement delivered $25M upfront.
1-for-80 reverse stock split completed September 2026 to regain Nasdaq minimum bid price compliance; trading continues as GOSS.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.